- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00165100
Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer
December 20, 2007 updated by: Dana-Farber Cancer Institute
Dynamic Area Telethermometry (DAT) as an Auxiliary Imaging Modality in Assessment of Patients With Cancer
The purpose of this study is to evaluate whether this new method of taking pictures called Dynamic Area Telethermometry (DAT) might be a good way of looking at patients with cancer that is relatively close to the surface of the body.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
- The DAT system resembles a video camera which picks up changes in body temperature which may reflect disease-related changes in blood flow to some areas, particularly those involved with tumors.
- Patients with known tumor sites amendable to DAT evaluation will be imaged at the time of staging and at later time points. Thermal profiles will be compared to those of normal adjacent tissues and correlated with the images of the tumors on conventional images.
Study Type
Interventional
Enrollment
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber Cancer Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically confirmed malignancy
- Primary or secondary tumor location amendable to DAT scanning: subcutaneous tissues
- Older than 15 years of age
- Able to withhold movement for 20 seconds, hold breath for 20 seconds for chest wall lesions and clinically stable acutely
Exclusion Criteria:
- Uncontrolled motion
- Tumors not verified or measurable by standard imaging
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To assess the feasibility of DAT in tumors detected by conventional imaging and evaluation of therapy induced changes in DAT imaging profile over time.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Milos Janicek, MD, PhD, Dana-Farber Cancer Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2000
Primary Completion (Actual)
October 1, 2002
Study Completion (Actual)
October 1, 2002
Study Registration Dates
First Submitted
September 9, 2005
First Submitted That Met QC Criteria
September 9, 2005
First Posted (Estimate)
September 14, 2005
Study Record Updates
Last Update Posted (Estimate)
December 28, 2007
Last Update Submitted That Met QC Criteria
December 20, 2007
Last Verified
December 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 99-331
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Tumors
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedMalignant Tumors | Refractory TumorsFrance
-
Peking Union Medical College HospitalPeking University; Peking University Cancer Hospital & InstituteRecruiting
-
Bristol-Myers SquibbOno Pharmaceutical Co. LtdCompletedMalignant TumorsJapan
-
InnoPharmax Inc.CompletedMalignant TumorsTaiwan, United States
-
Nanjing Leads Biolabs Co.,LtdRecruiting
-
Memorial Sloan Kettering Cancer CenterRecruitingMalignant Solid TumorsUnited States
-
LaNova Medicines LimitedSuspendedMalignant TumorsChina
-
SUNHO(China)BioPharmaceutical CO., Ltd.RecruitingAdvanced Malignant TumorsChina
-
Fudan UniversityRecruitingAdvanced Malignant TumorsChina
-
AkesoRecruitingAdvanced Malignant TumorsChina